PX 329
Alternative Names: PX-26329; PX-329; PX-L329Latest Information Update: 28 May 2021
At a glance
- Originator Phenex Pharmaceuticals
- Class Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action Liver X receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in Germany (PO)
- 28 May 2021 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Germany (PO)
- 10 Apr 2019 Pharmacodynamics data from preclinical studies in Non-alcoholic steatohepatitis presented at the International Liver Congress 2019 (ILC-2019)